What is the current valuation of the Drug Allergy Market as of 2024?

The Drug Allergy Market was valued at 19.08 USD Billion in 2024. Read More

What is the projected market valuation for the Drug Allergy Market in 2035?

The market is projected to reach 54.06 USD Billion by 2035. Read More

What is the expected CAGR for the Drug Allergy Market during the forecast period 2025 - 2035?

The expected CAGR for the Drug Allergy Market during 2025 - 2035 is 9.93%. Read More

Which companies are considered key players in the Drug Allergy Market?

Key players include Pfizer, Novartis, Sanofi, Bristol-Myers Squibb, Merck & Co., GlaxoSmithKline, AstraZeneca, Johnson & Johnson, and AbbVie. Read More

What are the main segments of the Drug Allergy Market?

The main segments include Type, Treatment, Diagnosis, and End-Users. Read More

How did the nonimmunologic segment perform in 2024?

The nonimmunologic segment was valued at 7.63 USD Billion in 2024 and is projected to reach 21.06 USD Billion. Read More

What is the valuation of the treatment of anaphylaxis segment in 2024?

The treatment of anaphylaxis segment was valued at 5.0 USD Billion in 2024 and is expected to grow to 15.0 USD Billion. Read More

What is the projected growth for skin tests in the Drug Allergy Market?

Skin tests were valued at 4.0 USD Billion in 2024 and are projected to reach 12.0 USD Billion. Read More

Which end-user segment is expected to dominate the Drug Allergy Market?

The hospitals & clinics segment is expected to dominate, growing from 10.0 USD Billion in 2024 to 30.0 USD Billion. Read More

What does the future hold for the Drug Allergy Market in terms of growth?

The Drug Allergy Market appears poised for substantial growth, with projections indicating a significant increase in valuation by 2035. Read More

Drug Allergy Market

ID: MRFR/Pharma/2716-HCR

84 Pages

Satyendra Maurya

Last Updated: May 15, 2026

Drug Allergy Market Size, Growth and Industry Trends By Type (Immunologic, Nonimmunologic, And Others), Diagnosis (Skin Tests, Blood Tests, And Others), By Treatment (Antihistamines, Corticosteroids, And Others), By End User- Forecast Till 2035

Drug Allergy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)9.93%

2024 Market Size$ 19.08 Billion

2025 Market Size$ 20.97 Billion

2035 Market Size$ 54.06 Billion

Key Players

Pfizer

Novartis

Sanofi

Bristol-Myers Squibb

Merck & Co.

GlaxoSmithKline

Trends

Rising Awareness and Education
Advancements in Diagnostic Technologies
Regulatory Changes and Safety Protocols

Opportunities

Rising Healthcare Expenditure
Increasing Incidence of Drug Allergies
Growing Demand for Personalized Medicine

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 nonimmunologic
  2. 4.1.2 immunologic
  3. 4.1.3 others
2. 4.2 Healthcare, BY Treatment (USD Billion)
  1. 4.2.1 corticosteroids
  2. 4.2.2 withdrawal of the drug
  3. 4.2.3 antihistamines
  4. 4.2.4 treatment of anaphylaxis
  5. 4.2.5 others
3. 4.3 Healthcare, BY Diagnosis (USD Billion)
  1. 4.3.1 blood tests
  2. 4.3.2 skin tests
  3. 4.3.3 patch tests
  4. 4.3.4 others
4. 4.4 Healthcare, BY End-Users (USD Billion)
  1. 4.4.1 academic institutes
  2. 4.4.2 medical research centers
  3. 4.4.3 hospitals & clinics
  4. 4.4.4 others
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GlaxoSmithKline (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AbbVie (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY DIAGNOSIS
6. 6.6 US MARKET ANALYSIS BY END-USERS
7. 6.7 CANADA MARKET ANALYSIS BY TYPE
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT
9. 6.9 CANADA MARKET ANALYSIS BY DIAGNOSIS
10. 6.10 CANADA MARKET ANALYSIS BY END-USERS
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT
14. 6.14 GERMANY MARKET ANALYSIS BY DIAGNOSIS
15. 6.15 GERMANY MARKET ANALYSIS BY END-USERS
16. 6.16 UK MARKET ANALYSIS BY TYPE
17. 6.17 UK MARKET ANALYSIS BY TREATMENT
18. 6.18 UK MARKET ANALYSIS BY DIAGNOSIS
19. 6.19 UK MARKET ANALYSIS BY END-USERS
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT
22. 6.22 FRANCE MARKET ANALYSIS BY DIAGNOSIS
23. 6.23 FRANCE MARKET ANALYSIS BY END-USERS
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT
26. 6.26 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
27. 6.27 RUSSIA MARKET ANALYSIS BY END-USERS
28. 6.28 ITALY MARKET ANALYSIS BY TYPE
29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT
30. 6.30 ITALY MARKET ANALYSIS BY DIAGNOSIS
31. 6.31 ITALY MARKET ANALYSIS BY END-USERS
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT
34. 6.34 SPAIN MARKET ANALYSIS BY DIAGNOSIS
35. 6.35 SPAIN MARKET ANALYSIS BY END-USERS
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USERS
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE
42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT
43. 6.43 CHINA MARKET ANALYSIS BY DIAGNOSIS
44. 6.44 CHINA MARKET ANALYSIS BY END-USERS
45. 6.45 INDIA MARKET ANALYSIS BY TYPE
46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT
47. 6.47 INDIA MARKET ANALYSIS BY DIAGNOSIS
48. 6.48 INDIA MARKET ANALYSIS BY END-USERS
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT
51. 6.51 JAPAN MARKET ANALYSIS BY DIAGNOSIS
52. 6.52 JAPAN MARKET ANALYSIS BY END-USERS
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USERS
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT
59. 6.59 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
60. 6.60 MALAYSIA MARKET ANALYSIS BY END-USERS
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT
63. 6.63 THAILAND MARKET ANALYSIS BY DIAGNOSIS
64. 6.64 THAILAND MARKET ANALYSIS BY END-USERS
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT
67. 6.67 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
68. 6.68 INDONESIA MARKET ANALYSIS BY END-USERS
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT
71. 6.71 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
72. 6.72 REST OF APAC MARKET ANALYSIS BY END-USERS
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT
76. 6.76 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
77. 6.77 BRAZIL MARKET ANALYSIS BY END-USERS
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT
80. 6.80 MEXICO MARKET ANALYSIS BY DIAGNOSIS
81. 6.81 MEXICO MARKET ANALYSIS BY END-USERS
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT
84. 6.84 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
85. 6.85 ARGENTINA MARKET ANALYSIS BY END-USERS
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USERS
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USERS
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USERS
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT
101. 6.101 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
102. 6.102 REST OF MEA MARKET ANALYSIS BY END-USERS
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END-USERS, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END-USERS, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.2.4 BY END-USERS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.3.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.3.4 BY END-USERS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.4.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.4.4 BY END-USERS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.5.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.5.4 BY END-USERS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.6.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.6.4 BY END-USERS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.7.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.7.4 BY END-USERS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.8.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.8.4 BY END-USERS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.9.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.9.4 BY END-USERS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.10.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.10.4 BY END-USERS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.11.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.11.4 BY END-USERS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.12.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.12.4 BY END-USERS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.13.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.13.4 BY END-USERS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.14.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.14.4 BY END-USERS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.15.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.15.4 BY END-USERS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.16.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.16.4 BY END-USERS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.17.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.17.4 BY END-USERS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.18.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.18.4 BY END-USERS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.19.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.19.4 BY END-USERS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.20.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.20.4 BY END-USERS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.21.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.21.4 BY END-USERS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.22.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.22.4 BY END-USERS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.23.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.23.4 BY END-USERS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.24.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.24.4 BY END-USERS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.25.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.25.4 BY END-USERS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.26.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.26.4 BY END-USERS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.27.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.27.4 BY END-USERS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.28.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.28.4 BY END-USERS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.29.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.29.4 BY END-USERS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.30.3 BY DIAGNOSIS, 2025-2035 (USD Billion)
  4. 7.30.4 BY END-USERS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Drug Allergy Market Segmentation

Drug Allergy Market By Type (USD Billion, 2025-2035)

nonimmunologic
immunologic
others

Drug Allergy Market By Treatment (USD Billion, 2025-2035)

corticosteroids
withdrawal of the drug
antihistamines
treatment of anaphylaxis
others

Drug Allergy Market By Diagnosis (USD Billion, 2025-2035)

blood tests
skin tests
patch tests
others

Drug Allergy Market By End-Users (USD Billion, 2025-2035)

academic institutes
medical research centers
hospitals & clinics
others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”